BASi Appoints Preclinical VP

Philip A. Downing has been promoted to vice president of Preclinical Services at BASi.
 
Mr. Philip has worked at BASi for 18 years, starting as an analytical chemist and gaining responsibilities in more progressive leadership roles throughout his tenure. Mr. Downing worked for a clinical research laboratory, GFi Pharmaceuticals (now Covance Labs) as an analytical scientist designing and validating radiolabeled and non-radiolabeled assays used to support clinical ADME studies.  
 
“Since joining BASi in 1997, Philip has always maintained a high level of focus on our clients’ needs throughout the full range of both GLP and non-GLP Preclinical and Nonclinical services including Discovery, PKPD, acute & chronic toxicology, DART, juvenile toxicology, and carcinogenicity studies supporting IND and NDA enabling programs offered at the BASi facility located near Evansville, IN. Under Philip’s leadership, we will broaden our collaborative outreach and build on an already outstanding track record of supporting our clients’ drug discovery and early-stage development efforts,” said Jacqueline Lemke, president and chief executive officer of BASi.